Detalhe da pesquisa
1.
Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL.
Br J Haematol
; 204(2): 487-491, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37669920
2.
Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion.
Blood
; 140(25): 2709-2721, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36206503
3.
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.
Intern Med J
; 54(2): 328-336, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146232
4.
Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia.
Intern Med J
; 53(11): 2115-2118, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37950615
5.
Chronic lymphocytic leukaemia Australasian consensus practice statement.
Intern Med J
; 53(9): 1678-1691, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743239
6.
COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
Br J Haematol
; 197(1): 41-51, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34962656
7.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731259
8.
Immunoglobulin replacement therapy in chronic lymphocytic leukaemia patients with hypogammaglobulinaemia and infection.
Eur J Haematol
; 108(6): 460-468, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35152500
9.
Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
Br J Haematol
; 193(3): 556-560, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33851417
10.
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Blood
; 133(19): 2031-2042, 2019 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842083
11.
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.
Intern Med J
; 51(5): 763-768, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34047035
12.
Karyotype and outcome in CLL.
Blood
; 142(5): 402-404, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37535371
13.
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
Med J Aust
; 212(10): 481-489, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32401360
14.
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.
Intern Med J
; 50(6): 667-679, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32415723
15.
Molecular pathogenesis of chronic lymphocytic leukaemia.
Br J Haematol
; 186(5): 668-684, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31364161
16.
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood
; 129(19): 2612-2615, 2017 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28373262
17.
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Am J Hematol
; 94(12): 1353-1363, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31512258
18.
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
Mycoses
; 62(12): 1140-1147, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31520441
19.
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.
Br J Haematol
; 182(5): 654-669, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29978459
20.
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.
Br J Haematol
; 182(3): 360-372, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29767411